Navigation Links
Endeavor Power Corporation Introduces Its Proprietary FDA Cleared Target System Platform Technology
Date:3/8/2013

CAMBRIDGE, Mass., March 8, 2013 /PRNewswire/ -- Endeavor Power Corporation ("Endeavor Power" or the "Company") (OTCQB: EDVP) introduces its proprietary FDA Cleared Target System Platform Immunoassay Testing Technology ("Target System"). Endeavor Sciences, Inc. ("Endeavor"), the Company's operating wholly owned subsidiarity is pleased to announce the introduction of the Target System, Endeavor's FDA Approved Immunoassay Testing Platform to target the Point-Of-Care Testing (POCT) market.  The Company's diagnostic technology provides a cheaper, more efficient and timely alternative to centralized lab testing and represents a disruptive breakthrough innovation in the bio-medical and healthcare industries.

Endeavor's Target System provides a solution to the soaring costs of healthcare in the US and globally. It will revolutionize and alleviate the decline in revenues of Physicians and the reduction in quality of healthcare service currently available to patients.  A laboratory test that would normally take days for results, can now be performed at the time the patient and healthcare worker interact by utilizing the Target System.  The Target System Solution is modeled on:

  • Reducing the cost of diagnostic tests for patients through reduction of co-pay insurance payments.
  • Reducing the cost of diagnostic tests to medical insurance companies by reducing the cost of the test.
  • Increase the quality of healthcare by providing healthcare workers with results at the time they meet and interact with patients.
  • Provide increased revenue opportunities for Physicians.
  • Provide a simple and easy training process that will allow single process training for those administering the tests.
  • Provide a "Single Platform Solution" for a broad array of tests.
  • Endeavor Target System's high level of sensitivity can detect minute changes in the concentration of analytes necessary to perform difficult immunoassays, while the dynamic range allows resolution to be optimized to suit a full range of frequently ordered diagnostic tests.  This combination of qualitative and quantitative tests on the same platform, allows Endeavor to bring differentiation to the POCT market with a uniquely broad test menu of the following:

  • Controlled Flow-Through Rapid Immunoassay Test
  • Endeavor's US Patent Pending Target System Diagnostics Platform offers an array of improved modifications and features to the traditional Flow-through Immunoassay Test. With its Platform uniformity, patented vacuum pump, absorption layer for sample overflow, and complete compatibility with our optic reader, the Target System Diagnostics Platform is a unique collection of tests for qualitative and quantitative detection of conditions.

  • The Patented Target System "Vacuum Control Flow Device"
  • No other device on the market provides the clinician with "point of care device controls."

    Endeavor's Target System utilizes a patented vacuum and specimen absorption capability built right in. This innovative technology allows for the Target System platform to be utilized for multiple specimen sources including whole blood, serum, plasma, urine and feces.

  • Ease Of Use
  • The patented platform provides tremendous flexibility in sample requirements, clinician training and result interpretation. Our "train once" system means the clinician can now perform a number of single use tests on a wide variety of conditions with the interpretation of results consistent through the platform paradigm.

  • Unlimited Application
  • The unique vacuum pump action reduces test time and ensures maximum contact with the membrane antibodies. This patented collection device is virtually unlimited in the number of different tests that can be incorporated. The company plans to introduce a broad array of tests.

    Endeavor CEO, J. Michael Redmond commented, "The various value propositions created by Endeavor's Target System are quite numerous and I believe allow for Endeavor to have a distinct competitive advantage by allowing for the delivery of superior test results, a capacity for a large number of test interoperability, while you watch rapid test result capability and a simple, proven, robust 'train once' platform that delivers an economy of scale unmatched by our competitors."  Mr. Redmond added further, "We are quite fortunate to start our business with proven technology that is fully developed with 100% regulatory approval to initiate the commercialization of our business. A proven technology allows us to get to market quickly and with significant risk mitigation."

    ABOUT ENDEAVOR POWER CORPORATION Endeavor Power Corp is a fully reporting Nevada corporation traded on the OTCQB under the symbol "EDVP.QB".  The Company is headquartered in Cambridge, MA.  The Company's wholly owned subsidiary Endeavor Sciences, Inc. ("Endeavor") is a bio-medical company focused on infectious diseases, which owns a line of proprietary, FDA approved, Point of Care diagnostic tests on a single proprietary platform.  Endeavor is developing a novel, handheld diagnostic testing system that is simple, rapid and elegant, offering the potential to transform the diagnostic landscape by transitioning critical tests from the centralized lab directly to the hands of the physician or clinicians.  Our focus is on tests that detect and/or monitor infectious diseases. The Company's tests combine innovative technologies that provide accessible, practical and rapid point of care in vitro diagnostics are based on the Company's Target System, its FDA Approved Platform that centered on the Target System VT1000, its FDA Approved bench top fluorescence immunoassay spectrum analyzer and its innovative flow through Target System test cartridges. For more information: www.endeavorpowercorp.com and www.endeavorsciences.com

    Forward-Looking Statements

    This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our reports filed with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. Media Contact:

    Kyle W. Withrowkylew@endeavorpower.com.com Investor Contact:

    Mark BernhardCapital Group Communicationsmark@capitalgc.com 415.332.7200


    '/>"/>
    SOURCE Endeavor Power Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Drugs.com Launches iOS and Android Mobile App to Empower Patients and Providers Alike
    2. Agent of Change: Ford Empowers Women and Saves Lives in Rural India through New Technology, SUV Capabilities
    3. Leviton Introduces Medical-Grade Power Strips for Use in Patient-Care Areas
    4. Power Wheelchairs Supplier MedSupplyShop.com Highlights Upcoming Changes to Medicare Competitive Bidding Program
    5. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
    6. Varian Medical Systems Supports Program to Tap Brain Power of Research and Development Community in Russia
    7. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
    8. TI introduces lowest-power octal, 100-MSPS ADC for medical, industrial imaging applications
    9. Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment
    10. Free Research Report on Ford Motor Co., Pfizer, Inc., Barclays Bank PLC, General Electric Co. and PowerShares QQQ Trust
    11. Quest Announces Battery-Powered Mobile Wireless Surgical Video Display Solution
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
    (Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
    (Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
    (Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
    (Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
    (Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
    (Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
    Breaking Medicine News(10 mins):